Reliable Detection and Quantification of Protein Impurities
Automatic and reliable detection and quantification of low concentrated protein impurities down to 0.05% and below with the Agilent 2100 Bioanalyzer!
The Agilent 2100 Bioanalyzer together with the Agilent High Sensitivity Protein 250 Kit allows you to reliably detect and quantify low concentrated impurities next to massive main components – down to 0.05% and below. This meets the ICH guideline Q3B(R2): Impurities in New Drug Products! Reporting threshold 0.05% for a maximum daily dose >1g.
The Agilent 2100 Bioanalyzer provides:
- sensitivity and linear dynamic range – silver stain sensitivity down to 1 pg/μL of labeled protein on chip and 4 orders of magnitude in linear dynamic range
- fast results – complete automated analysis of 10 samples in 30 minutes
- reproducibility – qualitative, user-independent and digital data
- ease of use – standardized assay, pre-packaged reagent kits
- 21 CFR Part 11 compliance – validated reagents and software plus Agilent compliance services to meet all GMP/GLP needs
The High Sensitivity Protein 250 kit provides the first microfluidic assay for protein detection in the low picogram range. Therefore, the kit is suited excellent to solve typical protein QA/QC questions and to comply with ICH and FDA guidelines – in the Bioanalyzer-like, fast and reproducible way.
Learn more!Receive a free Protein QC application CD!
Contact
Agilent Technologies, Inc.
Life Sciences and Chemical Analysis Group
5301 Stevens Creek Boulevard
Santa Clara, CA 95051-7201
USA
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
